Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Robertson

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Contemporary Clinical Trials Communications|April 21, 2017
External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trialSheila M Bird, John Strang, Deborah Ashby, et al.
The Journal of Infectious Diseases|October 29, 2002
A genetic analysis of hepatitis C virus transmission between injection drug usersAlexandra Cochrane, Benjamin Searle, Alison Hardie, et al.
European Journal of Epidemiology|September 20, 2005
Do HIV disease progression and HAART response vary among injecting drug users in Europe?Liselotte van Asten, Robert Zangerle, Ildefonso Hernández Aguado, et al.
AIDS (London, England)|June 24, 2003
Tuberculosis risk varies with the duration of HIV infection: a prospective study of European drug users with known date of HIV seroconversionLiselotte van Asten, Miranda Langendam, Robert Zangerle, et al.
European Journal of Public Health|January 2, 2004
Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population levelLiselotte C van Asten, Faroudy Boufassa, Veronique Schiffer, et al.
The Journal of Infectious Diseases|January 15, 2004
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysisLiselotte van Asten, Inge Verhaest, Saida Lamzira, et al.
Harm Reduction Journal|April 4, 2023
Baseline characteristics of people experiencing homelessness with a recent drug overdose in the PHOENIx pilot randomised controlled trialRichard Lowrie, Andrew McPherson, Frances S Mair, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Contemporary Clinical Trials Communications|April 21, 2017
External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trialSheila M Bird, John Strang, Deborah Ashby, et al.
The Journal of Infectious Diseases|October 29, 2002
A genetic analysis of hepatitis C virus transmission between injection drug usersAlexandra Cochrane, Benjamin Searle, Alison Hardie, et al.
European Journal of Epidemiology|September 20, 2005
Do HIV disease progression and HAART response vary among injecting drug users in Europe?Liselotte van Asten, Robert Zangerle, Ildefonso Hernández Aguado, et al.
AIDS (London, England)|June 24, 2003
Tuberculosis risk varies with the duration of HIV infection: a prospective study of European drug users with known date of HIV seroconversionLiselotte van Asten, Miranda Langendam, Robert Zangerle, et al.
European Journal of Public Health|January 2, 2004
Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population levelLiselotte C van Asten, Faroudy Boufassa, Veronique Schiffer, et al.
The Journal of Infectious Diseases|January 15, 2004
Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysisLiselotte van Asten, Inge Verhaest, Saida Lamzira, et al.
Harm Reduction Journal|April 4, 2023
Baseline characteristics of people experiencing homelessness with a recent drug overdose in the PHOENIx pilot randomised controlled trialRichard Lowrie, Andrew McPherson, Frances S Mair, et al.
Pageof 5